December 27, 2012
Volcano Corporation Presentation At J.P. Morgan Conference To Be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the 31st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2013. The presentation by Scott Huennekens, president and CEO, will begin at 11 a.m., Pacific Standard Time (2 p.m., Eastern Standard Time). (Read more...)

December 5, 2012
Volcano Corporation Prices Offering Of $400 Million 1.75% Convertible Senior Notes Due 2017
Volcano Corporation (NASDAQ: VOLC) today announced the pricing of its public offering of $400 million aggregate principal amount of 1.75% convertible senior notes due December 1, 2017 registered under the Securities Act of 1933, as amended. Prior to August 7, 2017, the notes will be convertible only upon certain circumstances and during certain periods. (Read more...)

December 3, 2012
Volcano Corporation To Offer $350 Million Convertible Senior Notes Due 2017
Volcano Corporation (NASDAQ: VOLC) today announced its intention to offer, subject to market and other conditions, $350 million principal amount of convertible senior notes due December 1, 2017 in an offering registered under the Securities Act of 1933, as amended. Prior to August 7, 2017, the notes will be convertible only upon certain circumstances and during certain periods. (Read more...)

December 3, 2012
Volcano Corporation Announces Agreement To Acquire Crux Biomedical
Volcano Corporation (Nasdaq: VOLC) said today it has signed an agreement to acquire Crux Biomedical, a privately-held company that has developed a highly differentiated inferior vena cava (IVC) filter -- the Crux VCF System -- to treat pulmonary embolisms (PE's). (Read more...)

December 2, 2012
Fractional Flow (Chart) Reserve
Best medical practices for angioplasty and stent placement are a moving target because no sooner than a guideline is published it can be changed by the results of a more recent study. And the SCAI Ad Hoc PCI Consensus Statement posted online just three days ago is no exception. (Read more...)

November 23, 2012
Volcano Corporation Signs Agreement to Acquire Sync-Rx Ltd.
Volcano Corporation (Nasdaq: VOLC) today announced that it has entered into a definitive agreement to acquire Sync-Rx Ltd., a privately-held company based in Israel that develops advanced software applications that optimize and facilitate transcatheter cardiovascular interventions using automated online image processing. It is anticipated the transaction will close within the next 30 days. (Read more...)

November 16, 2012
Volcano Corporation Presentation At Piper Jaffray Conference To Be Webcast
Volcano Corporation (NASDAQ: VOLC) said today that it will be participating in the 24th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27. The presentation by Scott Huennekens, president and chief executive officer, will begin at 8:30 a.m., Eastern Standard Time (5:30 a.m., Pacific Standard Time). (Read more...)

November 14, 2012
Largest Prospective Study Shows IVUS-Guided Stent Placement Improves Patient Outcomes with Current Generation of Stents
Results from 3,349 patients, the largest study of its kind, show that stent procedures guided by intravascular ultrasound (IVUS) resulted in better patient outcomes and fewer complications at 30 days and 12 months compared to procedures without IVUS, and were safe. (Read more...)

October 25, 2012
Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Volcano Corporation (NASDAQ: VOLC) today announced it will report its operating results for the third quarter of fiscal 2012 on Tuesday, November 6. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time (5 p.m., Eastern Standard Time), Tuesday, November 6. (Read more...)

October 25, 2012
Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
Volcano Corporation announced today that St. Jude Medical agreed that previous versions of its PressureWire® products infringed Volcano's 6,976,965 patent (a pressure sensing guide wire patent). In addition, a jury in the federal district court in Delaware has issued a verdict in St. Jude Medical's favor in the Company's ongoing patent lawsuit with St. Jude Medical, finding that St. Jude Medical's PressureWire® products do not infringe three of Volcano's patents. (Read more...)

October 23, 2012
Volcano Announces Global Launch of PrimeWire Prestige® PLUS Pressure Guide Wire with AcuSense™ Technology
Volcano Corporation (Nasdaq: VOLC) today announced the global launch of the PrimeWire Prestige® PLUS pressure guide wire with AcuSense™ technology, which allows for more precise measurements when distal pressure is monitored for longer periods of time. (Read more...)

October 19, 2012
Volcano to Highlight New Technologies and Clinical Study Results at TCT 2012
Volcano Corporation (NASDAQ: VOLC) today announced plans to highlight its functional measurement technologies and clinical study results related to Intravascular Ultrasound (IVUS) catheters and Fractional Flow Reserve (FFR) guide wires, at the Transcatheter Cardiovascular Therapeutics (TCT) conference being held in Miami from October 22nd - 26th, 2012. (Read more...)

October 16, 2012
Infraredx and Philips Announce Collaboration to Develop a New Standard of Catheterization Lab Integration for True Vessel Characterization
The companies today announced they have signed a joint development and collaboration agreement that is focused on integrating Infraredx's true vessel characterization (TVC) Imaging System with Philips' Allura Xper catheterization (cath) lab imaging systems. This collaboration is intended to enable seamless access to the TVC Imaging System with Philips' Allura X-ray systems. (Read more...)

October 4, 2012
Volcano Announces CE Mark and 510(k) Clearance for New Visions® PV .035 Digital IVUS Catheter
Volcano Corporation said today it has received clearance to market its new Visions® PV .035 Digital IVUS Catheter in both the US and Europe. The new intravascular ultrasound catheter is designed to image large vessels and facilitate the use of less iodinated contrast in endovascular procedures. (Read more...)

September 15, 2012
Results of the ADVISE Registry Published
Commentary from the Editor's Blog: A new method for the functional measurement of intracoronary pressures and the severity of blockages has been developed by researchers at Imperial College in London. Called Instant Wave-Free Ratio™ (iFR) it does not require injection of a vasodilator drug, such as adenosine. The comprehensive results of the ADVISE Registry (ADenosine Vasodilator Independent Stenosis Evaluation) were recently presented at EuroPCR by Dr. Davies in May and have now been published online ahead of print in EuroIntervention. (Read more...)

August 29, 2012
Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
Volcano Corporation (NASDAQ: VOLC) said today that it will be participating in the Stifel Nicolaus 2012 Healthcare Conference on Wednesday, September 5. The presentation by John Dahldorf, chief financial officer, will begin at 9:10 a.m., Eastern Daylight Time (6:10 a.m., Pacific Daylight Time). (Read more...)

August 29, 2012
Medtronic and Volcano Pen Strategic Alliance to Offer Cardiac Cath Labs Stents, Balloons, Guide Wires, IVUS, FFR and More
This alliance means that hospital systems can now be supplied via a single contract not only the fastest-growing drug-eluting stent in the U.S. (and best-selling DES worldwide), the Resolute Integrity, but also the market-leading intravascular ultrasound (IVUS) system to help place that stent accurately, as well as the fractional flow reserve (FFR) tools to help decide if stenting is the best treatment for the patient, as the FAME and FAME 2 trials have shown. (Read more...)

August 28, 2012
New England Journal of Medicine Publishes FAME II Trial Results Revealing Better Patient Outcomes with FFR-Guided Cardiac Stenting
St. Jude Medical, Inc. (NYSE:STJ) today announced results of the FAME II Trial demonstrating that patients with FFR-guided stenting plus the best available medical therapy had superior outcomes to those treated with medical therapy alone. Results published online in the New England Journal of Medicine (NEJM) and presented at the ESC Congress 2012 revealed that use of the PressureWire(tm) (technology used to measure blood flow restriction in the coronary arteries) yielded an 86 percent relative risk reduction for unplanned re-admission to the hospital with urgent revascularization in patients with stable coronary artery disease. (Read more...)

August 28, 2012
Society for Cardiovascular Angiography and Interventions (SCAI) Statement on FAME 2
The FAME 2 trial will improve treatment strategies for patients with stable ischemic heart disease. FAME 2 indicates that angioplasty and stenting (also known as percutaneous coronary intervention, or PCI) plus the best available medications results in better outcomes than medications alone for patients who have significant blockages in their heart arteries, as measured by a test known as Fractional Flow Reserve (FFR). (Read more...)

August 28, 2012
FAME 2 Published in the New England Journal of Medicine; Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
Volcano Corporation (NASDAQ: VOLC) today celebrated the publication of the results of the FAME 2 trial in the New England Journal of Medicine (NEJM). Volcano also announced participation in the next major international functionally-guided study—ISCHEMIA that will include the newest PrimeWire® PRESTIGE PLUS Pressure Guidewires. (Read more...)

August 7, 2012
Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
Volcano Corporation (NASDAQ: VOLC) said today that it will be participating in the Canaccord Genuity 32nd Annual Growth Conference on Tuesday, August 14. The presentation by Scott Huennekens, president and chief executive officer, will begin at 10:30 a.m., Eastern Daylight Time (7:30 a.m., Pacific Daylight Time). (Read more...)

August 2, 2012
Volcano Corporation Reports 13% Growth In Second Quarter Revenues
Volcano Corporation (NASDAQ: VOLC) today said revenues for the second quarter of 2012 increased 13 percent over second quarter revenues a year ago. Moreover the revenue from fractional flow reserve disposables increases 38%, demonstrating tremendous growth in a technology that is being increasingly adopted by hospital systems. (Read more...)

July 23, 2012
Volcano Corporation Schedules Second Quarter Conference Call, Webcast
Volcano Corporation (NASDAQ: VOLC) today announced it will report its operating results for the second quarter of fiscal 2012 on Thursday, August 2. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time), Thursday, August 2, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Read more...)

June 12, 2012
Stent Decision-Making Using Functional Measurement: Fractional Flow Reserve (FFR) and Instant Wave-Free Ratio™ (iFR®) - What's in a Number?
Preliminary data, presented at this year's EuroPCR meeting, show increasingly that functional measurement is a critical part of the therapeutic decision-making process for cardiologists: whether to stent a blocked coronary artery or instead triage a patient to medical therapy alone. The first results from the FAME II Study were made available and a new tool for functional measurement was discussed: the technology of Instant Wave-Free Ratio™ (iFR®) which allows measurements similar to FFR but does not need to use adenosine. (Read more...)

June 12, 2012
Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
Volcano Corporation (NASDAQ: VOLC) said today that it will be participating in the Wells Fargo Securities 2012 Healthcare Conference on Tuesday, June 19. The presentation by John Dahldorf, chief financial officer, will begin at 9:30 a.m., Eastern Daylight Time (6:30 a.m., Pacific Daylight Time). (Read more...)

June 10, 2012
Can Using IVUS (Intravascular Ultrasound) Prevent Stent Thrombosis?
Commentary from the Editor's Blog: A recent paper, published online before print in SCAI's journal, Catheterization and Cardiovascular Interventions, yet again adds to the evidence that intravascular ultrasound (IVUS) imaging during PCI can improve stent placement and expansion in a way that may prevent stent thrombosis (ST). (Read more...)

June 1, 2012
Patient Alert: Proof That Having a Stent Placed Using Fractional Flow Reserve is Better for You!
In January 2012 a major trial called FAME II was stopped after only two-thirds of patients were enrolled -- because the data showed clearly that results for stable angina patients, whose stents were placed using this latest guidance technology, were so superior that regulators determined it was "unethical" to assign patients to the group getting drug treatment only, without stenting! (Read more...)

May 24, 2012
Volcano Corporation Presentation At Jefferies Conference To Be Webcast
Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Jefferies 2012 Global Healthcare Conference on Monday, June 4. The presentation by John Dahldorf, chief financial officer, will begin at 8 a.m., Eastern Daylight Time (5 a.m., Pacific Daylight Time). (Read more...)

May 21, 2012
Volcano's Proprietary iFR® Functionality Demonstrates Excellent Results in Presentations at EuroPCR 2012
Three datasets were presented for the first time at EuroPCR that expand the clinical data supporting Volcano's proprietary Instant Wave-Free Ratio™ Functionality (iFR® Functionality). The goal of iFR® Functionality is to provide a functional, lesion-specific assessment in seconds, without injecting a vasodilator drug to induce stress on the heart. (Read more...)

May 15, 2012
FAME II: Should Fractional Flow Reserve (FFR) Be Mandatory?
Commentary from the Editor's Blog: Earlier today, the opening day of EuroPCR, Dr. Bernard De Bruyne presented preliminary results from the FAME II trial which tested the diagnostic power of Fractional Flow Reserve to guide PCI (stenting) of the coronary arteries. He concluded in his remarks: "Whether a patient needs PCI, or is better off with medical treatment, the data thus far reveal that treatments based on FFR guidance provide superior outcomes." (Read more...)

May 15, 2012
FAME II Trial Demonstrates FFR-Guided PCI Superior to Medical Treatment in Preliminary Findings
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that data from the FAME II trial demonstrated a significant difference in the need for urgent revascularization when Fractional Flow Reserve (FFR)-guided assessment was used to direct treatment in patients with stable coronary artery disease. These highly statistically significant results validate the profound role that FFR-guided therapy has in improving patient outcomes. (Read more...)

May 14, 2012
Fractional Flow Reserve and Intravascular Imaging on Stage at EuroPCR
Starting tomorrow, the largest European meeting of interventional cardiologists begins in Paris, and for four days, physicians will be watching demonstrations, live cases and lectures about a wide range of technologies and techniques -- and Intravascular Imaging and Guidance will be a topic on many physician's minds, as more and more data is presented, demonstrating how these imaging modalities can make percutaneous coronary interventions (PCI) better. (Read more...)

May 14, 2012
Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
Volcano Corporation (NASDAQ: VOLC) today announced its plans to highlight its extensive product portfolio, strong product pipeline, and presentations on Fractional Flow Reserve (FFR) and Instant Wave-Free Ratio™ Functionality (iFR™) at EuroPCR 2012, a major cardiology meeting being held in Paris from May 15-18. (Read more...)

May 14, 2012
St. Jude Medical Continues Strong Show of PCI Optimization Technologies at EuroPCR
St. Jude Medical, Inc. today announced it will display a number of technologies from the company's wide array of clinical solutions and launch its next-generation PressureWire™ Fractional Flow Reserve (FFR) assessment guidewire at EuroPCR 2012. (Read more...)

May 7, 2012
Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
Volcano Corporation (NASDAQ: VOLC) said today that it will be participating in the 11th Annual JMP Securities Research Conference on Monday, May 14. The presentation by John Dahldorf, chief financial officer, will begin at 10:30 a.m., Pacific Daylight Time (1:30 p.m., Eastern Daylight Time). (Read more...)

May 3, 2012
Volcano Corporation Presentation At Deutsche Bank Conference To Be Webcast
Volcano Corporation (NASDAQ: VOLC) said today that it will be participating in the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8. The presentation by John Dahldorf, chief financial officer, will begin at 4:10 p.m., Eastern Daylight Time (1:10 p.m., Pacific Daylight Time). (Read more...)

May 2, 2012
Volcano Corporation Reports 12% Increase in 1st Quarter Revenues
For the quarter ended March 31, 2012, Volcano reported revenues of $90.4 million versus revenues of $81.0 million in the first quarter a year ago. Year-over-year medical segment revenues increased 15 percent in the first quarter of 2012. (Read more...)

April 23, 2012
Abbott and St. Jude Medical Broaden Alliance for Cardiovascular Products in the United States
Abbott (NYSE: ABT) and St. Jude Medical (NYSE: STJ) today announced Choice Alliance, a multi-year joint initiative that provides mutual U.S. customers access to a robust portfolio of interventional cardiology, cardiac rhythm management, electrophysiology and intravascular imaging and diagnostic technologies. (Read more...)

April 23, 2012
Volcano Corporation Schedules First Quarter Conference Call, Webcast
Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will report its operating results for the first quarter of fiscal 2012 on Wednesday, May 2. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time, (5 p.m., Eastern Daylight Time), Wednesday, May 2. (Read more...)

March 5, 2012
Volcano Corporation Presentation at Roth Conference to be Webcast
Volcano Corporation (NASDAQ: VOLC) said today that it will be participating in the Roth Capital 24th Annual Orange County Growth Stock Conference on Monday, March 12. The presentation by John Dahldorf, chief financial officer, will begin at 9 a.m., Pacific Daylight Time (12 p.m., Eastern Daylight Time). (Read more...)

February 22, 2012
Volcano Reports 14 Percent Increase in Fourth Quarter Revenues; Medical Segment Revenues Grow 20 Percent
For the quarter ended December 31, 2011, Volcano reported revenues of $92.7 million versus revenues of $81.2 million in the fourth quarter a year ago. Year-over-year medical segment revenues increased 20 percent in the fourth quarter of 2011. Industrial segment revenues in the fourth quarter declined 70 percent versus a year ago, due to reduced spending in the telecommunications sector. (Read more...)

February 9, 2012
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
Volcano Corporation (NASDAQ: VOLC) today announced it will report its operating results for the fourth quarter of fiscal 2011 on Wednesday, February 22. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time, (5 p.m., Eastern Standard Time), Wednesday, February 22, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Read more...)

January 21, 2012
FAME II Is Not the "Anti-COURAGE": Stents and Angioplasty in the Spotlight
There's been much talk this week, given the news that the FAME II clinical trial ended enrollment early, due to ethical concerns that were generated by the fact that patients randomized to Optimal Medical Therapy (OMT) alone were returning to the hospital in significant numbers for "urgent revascularization." So is this a reversal of the COURAGE trial results? Not according to the principal investigators of both the FAME II trial AND the COURAGE trial, whom I have spoken with in the past 48 hours. (Read more...)

January 18, 2012
Does FAME II Trump COURAGE? FFR: Key to Stents and Angioplasty
Commentary from the Editor's Blog: St. Jude Medical (NYSE:STJ) announced that it is stopping enrollment in its FAME II trial after only 2/3 of the planned patients were included. Why? Because the interim data so clearly favor the use of Fractional Flow Reserve (FFR) to guide stenting (PCI) in stable angina patients that the independent Data Safety Monitoring Board (DSMB) for the trial has concluded that it would be unethical to continue to randomize patients to optimal medical therapy (OMT) alone. Wait a minute! Did they say that using optimal medical therapy alone was unethical for the treatment of stable angina patients? That's pretty big news! (Read more...)

January 18, 2012
Independent Data Safety Monitoring Board Recommends St. Jude Medical's FAME II Clinical Trial Stop Enrollment Following Positive Interim Analysis
St. Jude Medical, Inc. (NYSE:STJ) announced today that an interim analysis of the FAME II trial has found a highly statistically significant reduction in the need for hospital readmission and urgent revascularization when Fractional Flow Reserve (FFR)-guided assessment was used to direct treatment in patients with coronary artery disease. As a result of the positive interim analysis, the FAME II independent Data Safety Monitoring Board (DSMB) has recommended investigators stop patient enrollment in this trial as the DSMB considers it unethical to continue to randomize patients to optimal medical therapy (OMT) alone. (Read more...)

January 9, 2012
Volcano Corporation Announces Preliminary 4QTR Revenues for 2011
Volcano Corporation (NASDAQ: VOLC) said today it expects total revenues for the fourth quarter of 2011 will be approximately $92.7 million, bringing expected full year 2011 revenues to approximately $343.5 million. (Read more...)

January 3, 2012
Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
Volcano Corporation (NASDAQ: VOLC) said today that it will be participating in the 30th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10. The presentation by Scott Huennekens, president and chief executive officer, will begin at 9:30 a.m., Pacific Standard Time. (Read more...)

December 7, 2011
ADVISE: New Tool May Help Determine Stent and Angioplasty Appropriateness
Results of ADVISE, a pilot study testing the validity of concept of a new adenosine-free assessment of stenosis severity, were published today in the Journal of the American College of Cardiology as an expedited manuscript. This proof of concept study also provided a correlation of iFR against fractional flow reserve (FFR). The r value in 157 stenoses measured was 0.90, virtual equivalence. (Read more...)

December 4, 2011
Stents, Angioplasty and PCI: The Uncertainty Principle (MEDICARE Style)
The question of the day, regarding whether or not to stent a coronary artery, is now being brought to the forefront by the U.S. government in the form of a Medicare "Demonstration Project". And by "brought to the forefront", I mean MONEY! -- as in "we won't pay you if we determine that the stent procedure was inappropriate." (Read more...)

December 2, 2011
Women's Heart Disease and Intravascular Ultrasound (IVUS)
More evidence that intravascular imaging is critically important -- a broadcast on CBS affiliate WGCL-TV in Atlanta shows how a type of coronary narrowing more typical in women may not be seen on a standard angiogram because it's evenly distributed along the arterial wall or channel and doesn't appear as a "spike" or sudden narrowing -- yet it may be restricting the flow of blood to the heart just the same. (Read more...)

November 29, 2011
iFR: A New Way to Judge Stents and Angioplasty for Coronary Blockages?
iFR is a faster and less invasive way of determining whether or not a blockage is ischemia-producing. It does not require adenosine infusion and it removes virtually all of the objections that a cardiologist may have to using functional measurement, rather than angiography alone. (Read more...)

November 22, 2011
Volcano Corporation Announces Presentations at Upcoming Investor Conferences
Volcano Corporation (NASDAQ: VOLC) said today that it will be participating in two upcoming investor conferences. On Tuesday, November 29, the company will participate in the 23rd Annual Piper Jaffray Health Care Conference. On Tuesday, December 6, the company will participate in the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference. (Read more...)

November 14, 2011
ADVISE Study Results Demonstrate the Instant Wave-Free Ratio™, a Vasodilator-Free Measure of Stenosis Severity, is Comparable to FFR
Volcano Corporation (NASDAQ: VOLC) and Imperial College London jointly announced the results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study during a Late Breaking Clinical Trial session at the Transcatheter Therapeutics Conference (TCT 2011) in San Francisco. The results have also been accepted for publication in the Journal of the American College of Cardiology. ADVISE assessed the ability of an investigational product called instant wave-Free Ratio™ (iFR™), to provide a measurement of the severity of a coronary stenosis that is similar to fractional flow reserve (FFR), the gold standard for assessing ischemia, without the need for pharmacologic vasodilation. (Read more...)

November 9, 2011
Upgraded ACCF/AHA/SCAI Guidelines Reinforce Benefits of Volcano's Precision Guided Therapy Technologies
Volcano Corporation (NASDAQ: VOLC) supports the elevation of Intravascular Ultrasound (IVUS) and Fractional Flow Reserve (FFR) technologies in the updated clinical guidelines for the management of patients undergoing percutaneous coronary intervention (PCI). The update was issued earlier this week by the American College of Cardiology Foundation (ACCF), American Heart Association (AHA), and Society for Cardiovascular Angiography and Interventions (SCAI). (Read more...)

November 4, 2011
Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011
Volcano Corporation (NASDAQ: VOLC) today announced that results from the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) clinical trial, sponsored by Volcano, will be presented in a Late-Breaking Session at Transcatheter Cardiovascular Therapeutics (TCT 2011), which is taking place from November 7-11 in San Francisco. Volcano also announced it is launching a new fractional flow reserve (FFR) pressure wire, the PrimeWire PRESTIGE™ PLUS, Volcano's newest FFR wire and the third pressure guidewire it has introduced in the last three years. (Read more...)

October 31, 2011
Volcano Reports 18% Increase in Total Third Quarter Revenues
Volcano Corporation (NASDAQ: VOLC) said today that revenues for the third quarter of 2011 increased 18 percent versus the third quarter of 2010. For the quarter ended September 30, 2011, Volcano reported revenues of $85.8 million versus revenues of $72.9 million in the third quarter a year ago. (Read more...)

October 28, 2011
Fractional Flow Reserve (FFR) Guides Stent Treatment for So-Called "Widow Maker" Artery
The results of this study show that a significant number of patients with a proximal Left Anterior Descending (LAD) blockage do not need angioplasty or bypass surgery and can be treated safely with medical therapy only. (Read more...)

October 28, 2011
Volcano Corporation Appoints Leslie V. Norwalk and Dr. Eric J. Topol to Board of Directors
Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guidance therapy tools designed to enhance the treatment of coronary and peripheral vascular disease, today announced the appointment of Leslie V. Norwalk, Esq., and Eric J. Topol, M.D., to the company's board of directors. (Read more...)

October 27, 2011
Volcano Corp Schedules Events for TCT 2011
Volcano Corporation has scheduled several events for this year's Transcatheter Cardiovascular Therapeutics (TCT) meeting, being held November 7-11 in San Francisco. These events will be highlighting their intravascular guidance technologies, in particular a new adenosine-free FFR technique. (Read more...)

October 17, 2011
Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the third quarter of fiscal 2011 on Monday, October 31. (Read more...)

September 27, 2011
New Techniques Can Help Doctors Decide Who Needs A Stent
Two emerging technologies can help doctors determine more precisely when and where to place a stent. Sometimes called “Intravascular Guidance Tools,” Intravascular Ultrasound (IVUS) and Fractional Flow Reserve (FFR) are images and measurements that give the doctor a closer look inside the artery, and more information about how well blood is flowing through the artery to the heart. (Read more...)

September 27, 2011
FFR: Why Isn't Everyone Using It?
Guidelines give FFR an "A", leaders in interventional cardiology say it is "a very important tool". Studies show it reduces "inappropriate stenting" and saves money. So why do less than 20% of PCIs take advantage of FFR? (Read more...)

September 27, 2011
An IVUS State of Mind
Images we see form a construct in our brains of what may be reality. For half-a-century, the 2-D shadow images of the coronary arteries, as served up by the "gold standard" of angiography, have informed cardiologists as to what a stenosis is. But newer intravascular imaging modalities have challenged those black-and-white renderings and are yielding a new, more accurate way to "see" and think about coronary artery lesions: "an IVUS state of mind". (Read more...)

September 1, 2011
Volcano Corporation Announces Presentations at Upcoming Investor Conferences
Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral vascular disease, said today that it will be participating in two upcoming investor conferences on September 7 and 8. (Read more...)

August 2, 2011
Volcano Corporation Presentation at Canaccord Genuity Conference to be Webcast
Volcano Corporation (NASDAQ: VOLC) said today that it will be participating in the 2011 Canaccord Genuity Growth Conference on Tuesday, August 9. The presentation by Scott Huennekens, president and chief executive officer, will begin at 11 a.m., Eastern Daylight Time (8 a.m., Pacific Daylight Time). (Read more...)

August 1, 2011
Volcano Reports 22 Percent Increase in Second Quarter Medical Segment Revenues and Earnings per share of $0.09
Volcano Corporation (NASDAQ: VOLC) said today that revenues for the second quarter of 2011 increased 14 percent versus the second quarter a year ago in total, including a 22 percent increase in medical segment revenues versus the second quarter a year ago. "During the quarter, we continued to successfully drive our initiatives to achieve market share gains and increase utilization for our core FM (Functional Management) and IVUS (Intravascular Ultrasound) offerings. Year-over-year revenues from the sale of IVUS and FM disposables increased 22 percent and 54 percent, respectively," said Scott Huennekens, president and chief executive officer of Volcano. (Read more...)

July 18, 2011
Volcano Corporation Schedules Second Quarter Conference Call, Webcast
Volcano Corporation (NASDAQ: VOLC) today announced that it will report its operating results for the second quarter of fiscal 2011 on Monday, August 1. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time), Monday, August 1, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Read more...)

June 17, 2011
Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
Volcano Corporation (NASDAQ: VOLC) said today that it will be participating in the 2011 Wells Fargo Securities Healthcare Conference on Wednesday, June 22. The presentation by John Dahldorf, chief financial officer, will begin at 9:30 a.m., Eastern Daylight Time (6:30 a.m., Pacific Daylight Time). (Read more...)

June 10, 2011
Volcano Corporation Presentation at William Blair Conference to be Webcast
Volcano Corporation (NASDAQ: VOLC) said today that it will be participating in the William Blair & Company 31st Annual Growth Stock Conference on Thursday, June 16. The presentation by Scott Huennekens, president and chief executive officer, will begin at 8:40 a.m., Central Daylight Time (9:40 a.m., Eastern Daylight Time). (Read more...)

May 31, 2011
Volcano Corporation Presentation at Goldman Sachs Conference to be Webcast
Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral vascular disease, said today that it will be participating in the Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8. (Read more...)

May 28, 2011
Boston Scientific Recalls iCross™ Intravascular Ultrasound (IVUS) Coronary Imaging Catheters
Boston Scientific Corporation (NYSE: BSX) announced on Friday that it is voluntarily recalling all of its iCross™ Coronary Imaging Catheters due to reports of catheter tip detachments caused by embrittlement of the catheter material. The company reports that the recall affects almost 30,000 units distributed in the United States, Puerto Rico, Trinidad, Tobago and the American Virgin Islands. (Read more...)

May 26, 2011
Statement From Volcano Corporation on Latest St. Jude Lawsuit
Volcano Corporation (NASDAQ: VOLC) commented on a new lawsuit filed May 24, 2011 by St. Jude Medical in a Delaware court, reprising many of the claims that were recently decided (in Volcano's favor) by a Massachusetts court. Volcano stated that it "denies these unfounded allegations. Volcano firmly believes that this latest lawsuit has no merit, and looks forward to the opportunity to proving so in court." (Read more...)

May 16, 2011
Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR
Volcano Corporation (NASDAQ: VOLC) today announced its participation in the Paris course for Revascularization (EuroPCR) from May 17 - 20. Volcano's focus will be on highlighting the strength of its product portfolio, which includes innovative devices like the Vascular Imaging Balloon Catheter (VIBE® RX), and its sponsorship of a symposium that highlights the use and value of Precision Guided Therapy in clinical practice today. (Read more...)

May 4, 2011
Volcano Corporation to Supply Intravascular Ultrasound Technology to Covidien for Integration with Plaque Excision Systems
Volcano Corporation (NASDAQ: VOLC) today announced the signing of a supply agreement with ev3, a Covidien company, under which Volcano will supply its proprietary Intravascular Ultrasound (IVUS) technology for use in ev3's Plaque Excision Systems. Utilizing the digital IVUS transducer incorporated in Volcano's market leading EagleEye® catheter product line, this new product will be capable of running on Volcano's global installed base of 5,000 systems. (Read more...)

May 4, 2011
Volcano Achieves 22 Percent Increase in First Quarter Revenues; Sales Growth, Margin Expansion Drive Profitability
Volcano Corporation (NASDAQ: VOLC) said today that revenues in the first quarter of 2011 increased 22 percent versus revenues in the first quarter of 2010. For the quarter ended March 31, 2011, Volcano reported revenues of $81.0 million, compared with revenues of $66.6 million in the first quarter a year ago, and gross margin was 65.6 percent in the first quarter of 2011 compared to gross margin of 60.0 percent in the first quarter a year ago. (Read more...)

May 4, 2011
Volcano Corporation Presentation at Bank of America Merrill Lynch Conference to be Webcast
Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral vascular disease, said today that it will be participating in the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 11. (Read more...)

April 29, 2011
St. Jude Medical Sponsored Study Determines FFR Can Improve Health while Reducing Economic Burden to German Healthcare System
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that an analysis of the benefits to using a Fractional Flow Reserve (FFR)-guided intervention strategy found that the technology can improve patient outcomes while saving millions of Euros. The analysis demonstrates that routine use of FFR could reduce the number of deaths and heart attacks of German citizens while also saving a potential 14,000,000EUR in 2011 and 2012. (Read more...)

April 25, 2011
Volcano Corporation Schedules First Quarter Conference Call, Webcast
Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the first quarter of fiscal 2011 on Wednesday, May 4. (Read more...)

April 5, 2011
Volcano Announces the Introduction of the PrimeWire PRESTIGE® Pressure Guide Wire in Japan
Volcano Corporation (NASDAQ: VOLC) today announced it has received clearance to market the PrimeWire PRESTIGE® pressure guide wire in Japan. In addition to accurately measuring intravascular pressure via Fractional Flow Reserve (FFR), the PrimeWire PRESTIGE® pressure guide wire delivers superior handling with a frontline tip design, enhanced torque and more support. (Read more...)

April 2, 2011
Volcano Corporation Announces Presentations at American College of Cardiology 2011
Volcano Corporation (NASDAQ: VOLC) today announced its participation in the 60th Annual Scientific Session of the American College of Cardiology (ACC) from April 2nd to April 5th, 2011 in New Orleans. (Read more...)

March 10, 2011
Volcano Corporation Presentation at Roth Capital Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the Roth 23rd Annual Orange County Growth Stock Conference on Monday, March 14. (Read more...)

March 8, 2011
Volcano Corp CEO Scott Huennekens to Ring NASDAQ Bell
Tomorrow Volcano Corporation (NASDAQ:VOLC) holds its 2011 Analyst Day at the NASDAQ MarketSite in New York City and, to start the festivities off, President And Chief Executive Officer Scott Huennekens will ring the NASDAQ Stock Market Opening Bell. (Read more...)

March 4, 2011
Volcano Announces the Introduction of the Eagle Eye® Platinum Digital IVUS Catheter at the 20th PCI Live Demonstration Course in Kurashiki
Volcano Corporation (Nasdaq: VOLC) announced today that it received clearance to market the Eagle Eye® Platinum digital IVUS catheter in Japan. Full market release of Eagle Eye® Platinum in Japan is expected in the second quarter of 2011. This state-of-the-art catheter offers all of the benefits of the predecessor Eagle Eye® Gold catheter, plus improved deliverability and the convenience of additional radiopaque markers. (Read more...)

March 1, 2011
Volcano Corporation Announces Webcast of March 9th Analyst Day
Volcano Corporation (Nasdaq: VOLC) will hold its 2011 Analyst Day on Wednesday, March 9, at the NASDAQ MarketSite in New York City. The webcast will begin at 10 a.m., Eastern Standard Time (7 a.m., Pacific Standard Time) and conclude at 2 p.m., Eastern Standard Time (11 a.m., Pacific Standard Time). (Read more...)

February 23, 2011
Volcano Reports Record Revenue and GAAP Profitability for 2010
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral vascular disease, today reported record revenues for the fourth quarter and all of fiscal 2010. (Read more...)

February 14, 2011
Laser Wars: Volcano Vindicated on OCT Trade Secret Suit
Last week the Superior Court of Massachusetts entered a Final Judgment in the latest round of "Laser Wars" being waged between Volcano Corporation and St. Jude Medical. Both companies "lasered up" a few years ago...and that has led to their "lawyering up" -- remember "Stent Wars"? So here's what happened.... (Read more...)

February 14, 2011
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC) will report its operating results for the fourth quarter and all of fiscal 2010 on Wednesday, February 23. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time, (5 p.m., Eastern Standard Time), Wednesday, February 23, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Read more...)

February 10, 2011
Final Superior Court Ruling on Trade Secret Lawsuit Favors Volcano Corporation and Its Axsun Subsidiary
Scott Huennekens, President and CEO of Volcano stated, "After two-plus years of litigation, we are gratified by the Court's decision. Neither Volcano nor Axsun used any of LightLab's purported trade secrets in Volcano's development of its OCT System, or Axsun's OCT tunable laser. With LightLab's trade secret allegations now behind us, we will continue to focus our energy on developing key products that improve patient care." (Read more...)

February 8, 2011
Fractional Flow Reserve: A "How-To" Guide for Cardiologists
In the December 1 issue of Catheterization and Cardiovascular Interventions, a team, headed by Dr. Bernard De Bruyne of Belgium, published a "how-to" guide on FFR titled, "Practical tips and tricks for the measurement of fractional flow reserve". (Read more...)

January 31, 2011
OCT Wars: St. Jude Versus the Volcano
Commentary from the Editor's Blog: It used to be "Stent Wars", but now we are seeing "OCT Wars", today at least, when a decision from the Massachusetts Superior Court was looked at in two entirely different ways. (Read more...)

January 31, 2011
Massachusetts Court Rules in Favor of Volcano and Against St. Jude Medical Subsidiary in Trade Secrets Case
Volcano Corporation (Nasdaq: VOLC) said today that the Superior Court of Massachusetts has issued a decision that ruled in favor of Volcano and its wholly-owned subsidiary Axsun Technologies, Inc., and against LightLab Imaging, Inc., on all of LightLab's remaining claims for trade secret misappropriation. The 11-page decision also rejected LightLab's request for injunctive relief. This ruling follows prior Court rulings, in October 2010 and December 2009, that rejected other LightLab's trade secret misappropriation claims. LightLab Imaging is a wholly-owned subsidiary of St. Jude Medical, Inc. (Read more...)

January 31, 2011
St. Jude Medical Announces Superior Court Ruling in Trade Secret Lawsuit Involving Its OCT Business and Volcano Corporation and Axsun Technologies
St. Jude Medical, Inc. (NYSE:STJ) today announced that the Superior Court of Massachusetts has issued rulings in outstanding litigation between LightLab Imaging Inc. (acquired last year by St. Jude Medical), Volcano Corporation (Nasdaq: VOLC) and its subsidiary Axsun Technologies, Inc. The rulings find that Volcano Corporation and Axsun Technologies violated a Massachusetts law against engaging in unfair competition and unfair or deceptive acts or practices, through a pattern of inappropriate conduct directed at key technology used in the company's Optical Coherence Tomography (OCT) product platform. (Read more...)

January 19, 2011
PROSPECT Study Published in NEJM Demonstrates That Volcano's IVUS and VH® IVUS Technologies Can Assess Risk of a Future Clinical Event Better Than Using Angiography Alone
Results from the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study, first presented at the TCT meeting in 2009, were published today in The New England Journal of Medicine, with supplemental material that was not part of the original presentation. Results showed that grayscale intravascular ultrasound (IVUS) and Volcano's proprietary VH® IVUS tissue characterization software enable physicians to more accurately assess the risk of individual blockages than the use of the current standard-of-care angiographic imaging alone. (Read more...)

January 10, 2011
Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2010 and Full Year 2010
Volcano Corporation (Nasdaq: VOLC) said today that it expects total revenues for the fourth quarter of 2010 will be approximately $81.0 million, bringing expected full year 2010 revenues to approximately $294.0 million. The company's revenue expectations for fiscal 2010 compare with prior guidance for revenues of $286.0-$290.0 million and reflect year-over-year revenue growth of approximately 29 percent. (Read more...)

January 4, 2011
Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11. The presentation by Scott Huennekens, president and chief executive officer, will begin at 9 a.m., Pacific Standard Time (12 p.m., Eastern Standard Time). (Read more...)

December 16, 2010
Fractional Flow Reserve (FFR) Makes Stent Procedures More Cost Effective -- and Better!
A report in this week's Circulation, the Journal of the American Heart Association, analyzes data from the highly-impactful FAME study and concludes: "Economic evaluation of the FAME study reveals that FFR-guided percutaneous coronary intervention in patients with multivessel coronary disease is one of those rare situations in which a new technology not only improves outcomes but also saves resources." (Read more...)

December 7, 2010
Fractional Flow Reserve and Stents
Interventional cardiologist William Fearon of Stanford sat down with Angioplasty.Org recently to talk about a better way to judge if a patient might benefit from a stent. Instead of looking at the x-ray angiogram and saying, "That's a 70% blockage -- let's put a stent in there and you'll feel much better," Dr. Fearon advocates the use of a thin pressure wire which actually measures the flow through the narrowing. The technology is called Fractional Flow Reserve or FFR. (Read more...)

December 7, 2010
Interview with William Fearon, MD
Co-principal investigator at Stanford of the FAME and FAME II studies and leader in the use of Fractional Flow Reserve (FFR) offers his assessment of FFR as a diagnostic tool for stenting (or not) and gives us a preview of FAME II, which is basically the COURAGE trial, guided by FFR. Also Dr. Fearon discusses some exciting developments in using pressure wires to measure microvasculature function. (Read more...)

December 1, 2010
Volcano Corporation Presentation at Canaccord Genuity Conference to Be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference on Tuesday, December 7. The presentation by John Dahldorf, chief financial officer, will begin at 11:30 a.m., Pacific Standard Time (2:30 p.m., Eastern Standard Time). (Read more...)

November 23, 2010
Volcano Corporation Presentation at Piper Jaffray Health Care Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral vascular disease, said today that it will be participating in the 22nd Annual Piper Jaffray Health Care Conference on Tuesday, November 30. The presentation by Scott Huennekens, president and chief executive officer, will begin at 2:30 p.m., Eastern Standard Time (11:30 a.m., Pacific Standard Time). (Read more...)

November 3, 2010
Volcano Reports 35% Increase in Third Quarter Revenues
Volcano Corporation (Nasdaq: VOLC) said today that revenues in the third quarter of 2010 increased 35 percent over revenues in the same period a year ago. The company's profitability on a GAAP basis improved $9.6 million year-over-year as it reported net income of $5.6 million in the third quarter of 2010. (Read more...)

October 27, 2010
To Stent or Not to Stent: That is the Question!
Dr. Mark Midei has now launched a countersuit against his former employer. At issue is whether or not he placed over 500 stents unnecessarily. Is there a better way to make these decisions? Yes. Fractional Flow Reserve. (Read more...)

October 26, 2010
Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the third quarter and first nine months of fiscal 2010 on Wednesday, November 3. (Read more...)

October 6, 2010
Massachusetts Court Rules in Favor of Volcano and Against St. Jude Subsidiary
In a 16-page decision, the Court rejected LightLab's claims for protection of five alleged trade secrets relating to laser technologies, and denied all of LightLab's requests for permanent injunctions. The ruling followed a two-week trial on five of a number of trade secret claims alleged by LightLab. A trial on the remaining trade secret claims has not yet been scheduled. (Read more...)

October 5, 2010
Go With the Flow: Fractional Flow Reserve, That Is
Commentary from the Editor's Blog: Last November, the AHA/ACC/SCAI updated their official guidelines, giving Fractional Flow Reserve (FFR) a Class "A" level of evidence. This past August, the European Society of Cardiology updated their official guidelines, boosting FFR to the highest possible endorsement. However, only about 15% of cath labs in the U.S. use this technology. So why aren't more using FFR, a functional measurement device which has been proven to reduce healthcare costs? (Read more...)

October 4, 2010
IVUS for Every Stent and Angioplasty?
Why does Dr. Pichard use IVUS on every angioplasty? Why is "spot-stenting" better than stenting "normal-to-normal"? Read the complete interview with the Director of the Cath Lab at Washington Hospital Center. (Read more...)

September 22, 2010
Volcano Reacts Positively to the New European PCI Guidelines That Raise FFR-Guided PCI to a Class I, Level of Evidence a Recommendation
The new guidelines recommend FFR to help detect ischemic-related lesions, when an imaging stress test is not available. There are both clinical and economic benefits to FFR. The FAME study demonstrated that adhering to an FFR-guided regimen for multi-vessel disease is cost-beneficial to the hospital and payers by reducing material costs by $675 per patient, lowering average length of hospitalization by 0.3 days and reducing the total patient treatment cost at 12-months by more than $2,000. (Read more...)

September 21, 2010
TCT 2010 Volcano Investor Event at TCT and Sessions of Interest
On Thursday, September 23 at 10:00am, Volcano will be hosting an investor and analyst event at this year's TCT. The keynote speaker will be Dr. Barry Rutherford, a leading interventional cardiologist, who will be discussing the limitations of angiography and that its use alone is not sufficient in the diagnosis and treatment of patients. Dr. Rutherford is director of the Interventional Cardiology Research Program at the Mid America Heart Institute of Saint Luke’s Hospital in Kansas City. In addition, Scott Huennekens, Volcano’s President and Chief Executive Officer, will provide a brief Q&A session will follow the formal presentations. (Read more...)

September 21, 2010
Volcano Drives Innovation Forward With Three New U.S. Product Launches at TCT 2010
Volcano Corporation (Nasdaq: VOLC) today announced the company's plans to launch Eagle Eye® Platinum, PrimeWire PRESTIGE™, and the s5™/s5i™ 3.2.1 Software at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting from September 21 - 25 in Washington DC. "At TCT this year, Volcano is launching three major new products designed to make FFR and intravascular imaging faster and easier," said Joe Burnett, Executive Vice President of Marketing. "In an economic environment that has challenged innovation, we are pleased to be in a position where we can talk about not one, but three new products. It is this track record of innovation, and our unique, integrated system that combines both imaging and FFR, that has helped us earn the number one market share position in the U.S." (Read more...)

September 21, 2010
Volcano Announces It Will End Distribution Agreement with Fukuda
Volcano Corporation (Nasdaq: VOLC), said today it has reached an agreement with Fukuda Desnhi Co., Ltd. to end its distribution agreement in Japan. This transaction follows the successful transition of its distribution from Goodman to direct in Japan in July 2009. Fukuda, which distributes Volcano IVUS offerings to the cardiology market only, currently serves approximately 180 centers and accounts for approximately 20 percent of Volcano's revenues in Japan--and approximately five percent of the company's total revenues. The transition will take effect on December 1, 2010. (Read more...)

September 20, 2010
Volcano Corporation Files Counterclaim Asserting St. Jude Infringes Three Volcano Patents; Answers St. Jude's Patent Infringement Claims
Volcano Corporation today said that it believes the patent infringement claims brought against the company by St. Jude Medical Systems AB and its affiliated companies are without merit. In a filing made today in the United States District Court for the District of Delaware, Volcano denies allegations that its PrimeWire(R) products infringe any valid claim of St. Jude's asserted patents. Moreover, as described in detail in its answer, Volcano believes that two of the asserted St. Jude patents are unenforceable because they were obtained through acts of fraud on the United States Patent and Trademark Office (USPTO). (Read more...)

September 15, 2010
Volcano Corporation Prices $100 Million 2.875 Percent Convertible Senior Notes Due 2015
Volcano Corporation (Nasdaq: VOLC) today announced the pricing of its offering of $100 million aggregate principal amount of 2.875 percent convertible senior notes due September 1, 2015 registered under the Securities Act of 1933, as amended. Prior to June 1, 2015, the notes will be convertible only upon certain circumstances. (Read more...)

September 13, 2010
Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015
Volcano Corporation (Nasdaq: VOLC) today announced its intention to offer, subject to market and other conditions, approximately $100 million principal amount of convertible senior notes due September 1, 2015 in an offering registered under the Securities Act of 1933, as amended (the "Securities Act"). Prior to June 1, 2015, the notes will be convertible only upon certain circumstances. Upon conversion, holders will receive up to the principal amount of the notes in cash and any excess conversion value in shares of Volcano's common stock. (Read more...)

September 1, 2010
InfraReDx Receives FDA Clearance for LipiScan IVUS Coronary Imaging System
LipiScan IVUS is the first cardiac catheter to combine intravascular ultrasound (IVUS) and near-infrared (NIR) spectroscopy to help cardiologists identify and characterize the plaques that complicate stenting and are associated with acute coronary events. The NIR spectroscopy identifies the chemical content of the plaques; the IVUS provides an image of plaque structure and stent features. The Company expects to conduct a broad commercial launch of the system within the U.S. by year-end 2010, and anticipates regulatory approval and launch in Europe during 2011. (Read more...)

August 31, 2010
New 2010 ESC Guidelines for Percutaneous Coronary Interventions Reinforce Importance of FFR in Treatment of Coronary Artery Disease
The ESC guidelines, which are intended to assist health care providers in clinical decision making, now classify FFR-guided treatment as "Class I, with level of evidence A." Level of evidence A is the highest level available, requiring the most clinical evidence, and is awarded only when data has been derived from multiple randomized clinical trials or meta-analyses. Class I indicates a general agreement that a given treatment or procedure is beneficial, useful, and effective. (Read more...)

August 9, 2010
The Un-Stent Wars: Call Out the Fractional Flow Reserves
Commentary from the Editor's Blog: St. Jude Medical (NYSE: STJ) is suing Volcano Corporation (Nasdaq: VOLC) over five patents used in St. Jude's Fractional Flow Reserve (FFR) PressureWire. What is FFR and why is it the subject of this lawsuit? (Read more...)

August 3, 2010
Volcano Corporation Presentation at Canaccord Genuity Growth Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the 30th Annual Canaccord Genuity Growth Conference on Tuesday, August 10. (Read more...)

July 30, 2010
Volcano Reports Record Quarterly Revenues and Profitability
The company reports on its 2nd Quarter, ending June 30, showing that year-to-date revenues increased 36%. The company also announced an advanced Forward-Looking Imaging Technology acquisition. (Read more...)

July 27, 2010
Volcano Will Strongly Defend Against St. Jude Lawsuit
Volcano Corporation (Nasdaq: VOLC) stated today that it will vigorously defend against the patent infringement lawsuit filed against it by St. Jude Medical in federal district court in Delaware. Volcano believes that the claims against it are entirely without merit, and looks forward to vindicating its rights in court. (Read more...)

July 27, 2010
St. Jude Medical Files Patent Infringement Lawsuit Against Volcano Corporation in the U.S.
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced today that it has filed a lawsuit against Volcano Corporation for patent infringement. The suit, which involves five St. Jude Medical patents and seeks injunctive relief and monetary damages, was filed in the United States District Court for the District of Delaware. (Read more...)

July 20, 2010
Volcano Corporation Schedules Second Quarter Conference Call, Webcast
Text Volcano Corporation (Nasdaq: VOLC), today announced that it will report its operating results for the second quarter and first six months of fiscal 2010 on Friday, July 30. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 5:30 a.m., Pacific Daylight Time (8:30 a.m., Eastern Daylight Time), Friday, July 30, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Read more...)

June 23, 2010
To Stent or Not To Stent: Fractional Flow Reserve (FFR) Trumps Angiography in Diagnosing Blockages up to 90%
The authors of a new study pubished in JACC conclude: "In patients with multivessel CAD, coronary angiography is an inappropriate tool to identify ischemia-producing stenoses as detected by the FFR. This discrepancy between angiographic and functional stenosis severity is not only present in the 50% to 70% stenosis range but also in the 71% to 90% stenosis range." (Read more...)

May 27, 2010
Stent Helpers: IVUS, OCT and FFR -- Intravascular Tools At EuroPCR
Commentary from the Editor's Blog: Three intravascular imaging/therapeutic modalities have been making news this month, both in the U.S. and in Paris at the EuroPCR meeting ending tomorrow. They are Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS) and Fractional Flow Reserve (FFR). (Read more...)

May 26, 2010
Volcano Introduces VIBE™ RX - the World’s Only Vascular Imaging Balloon Catheter
Volcano Corporation (NASDAQ: VOLC) announced today that it has received CE Mark approval for the VIBE™ RX Vascular Imaging Balloon Catheter. The company also announced that it has completed its first clinical cases with the VIBE™ RX in New Zealand. A single VIBE™ RX Catheter can quickly access, prepare, and assess challenging lesions. IVUS guidance provides precise, targeted balloon dilatation with immediate confirmation of interventional results. (Read more...)

May 25, 2010
St. Jude Medical Enrolls First Patient in FAME II Clinical Trial to Study Use of Fractional Flow Reserve Technology in Patients With Stable Coronary Artery Disease
St. Jude Medical, Inc. (NYSE:STJ) announced today at EuroPCR that the first patient was enrolled in the FAME II (Fractional Flow Reserve (FFR)-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment vs. Optimal Medical Treatment Alone in Patients with Stable Coronary Artery Disease) trial. The goal of the FAME II trial is to study the role of Fractional Flow Reserve (FFR) in the treatment of stable coronary artery disease by comparing the clinical outcomes, safety and cost effectiveness of percutaneous coronary intervention (PCI) guided by FFR plus optimal medical treatment (OMT) to OMT alone. (Read more...)

May 24, 2010
Volcano Announces Plans to Introduce Multiple New Products at EuroPCR 2010
Volcano Corporation (Nasdaq: VOLC) announced today the company's plans to highlight its new product launches, presence in live cases, and participation in late breaking trials during EuroPCR from May 25 - 28 in Paris. (Read more...)

May 20, 2010
Physicians Cite Positive First Clinical Experience with Volcano's Eagle Eye® Platinum Digital IVUS Catheter
Volcano Corporation (Nasdaq: VOLC) announced today the completion of the first clinical cases using the new Eagle Eye® Platinum digital IVUS catheter. The procedures were performed in seven centers within the United States. Commercial launch of Eagle Eye® Platinum in the U.S. is expected in June 2010. (Read more...)

May 20, 2010
Volcano Announces Positive Clinical Experience With Its Second Generation OCT Catheter, Prepares for U.S. Regulatory Study
Volcano Corporation (Nasdaq: VOLC) announced today the successful completion of Optical Coherence Tomography (OCT) cases with Volcano's second generation OCT catheter and system. Pending IDE approval, Volcano plans to use this OCT system in the US and South America as part of VOILA, a U.S. regulatory trial during 2010. Commercial release of Volcano's OCT system is expected in Europe in early 2011 and in the U.S. in mid-2011. (Read more...)

May 19, 2010
St. Jude Medical to Acquire LightLab Imaging
St. Jude Medical stated that its acquisition of Optical Coherence Tomography technology will provide the company with a product platform to compete in and potentially expand $500 million coronary imaging market. (Read more...)

May 19, 2010
Volcano Announces 510(k) Clearance, CE Mark Approval, and First Clinical Use for the PrimeWire PRESTIGE™ Pressure Guide Wire
Volcano Corporation (Nasdaq: VOLC) announced today it received both 510(k) clearance and CE Mark approval for its PrimeWire PRESTIGE™ Pressure Guide Wire for use with patients who have both single-vessel and multi-vessel disease. This next generation pressure wire is compatible with Volcano's full suite of integrated multi-modality consoles and stand-alone physiology systems as well as various hemodynamic monitoring systems. (Read more...)

May 5, 2010
LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States
LightLab Imaging, Inc. has received clearance from the US FDA for the C7-XR Imaging System and companion C7 Dragonfly Imaging Catheter. These products, incorporating LightLab's latest generation Frequency Domain OCT (FD-OCT™) technology, are currently approved in over 35 countries in Europe and Asia, and have been used by leading hospitals to perform high resolution imaging of vessel and lumen morphology in thousands of coronary interventions to date. (Read more...)

May 5, 2010
Volcano Corporation Presentation at Bank of America Merrill Lynch Health Care Conference to Be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 11. The presentation by Scott Huennekens, president and chief executive officer, will begin at 9:20 a.m., Eastern Daylight Time (6:20 a.m., Pacific Daylight Time). (Read more...)

May 3, 2010
Volcano Reports 36 Percent Increase in First Quarter Revenues
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues for the first quarter of 2010 increased 36 percent over the first quarter of 2009. (Read more...)

April 27, 2010
See One, Score One for Stents
Commentary from the Editor's Blog: Two technologies working together -- IVUS lets you see what the lesion looks like, and the AngioSculpt balloon lets you do something to improve the outcome of the stenting. (Read more...)

April 27, 2010
Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt® PTCA Scoring Balloon Catheter in Japan
Scott Huennekens, President and CEO of Volcano stated, "This relationship between Volcano and AngioScore now combines two technologies: Visualization with Volcano's intravascular imaging products to build a lesion specific strategy; and tailored therapy with the AngioSculpt Scoring Balloon Catheter to deliver a targeted treatment for that specific type of lesion. This concept of precision-guided therapy using intravascular imaging has already taken hold in Japan where the technique is used in more than 70% of all PCI procedures. Our distribution of the AngioSculpt device now gives us access to both parts of the equation - imaging and therapy." (Read more...)

April 26, 2010
Volcano Corporation Schedules First Quarter Conference Call, Webcast
The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time, (5 p.m., Eastern Daylight Time), Monday, May 3, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Read more...)

March 12, 2010
Volcano Expands Access to FFR with Ability to Integrate with the Majority of Hemodynamic Monitoring Systems
The value of Fractional Flow Reserve in guiding PCI (percutaneous coronary interventions) has been shown in the FAME studies, as well as others. Yet the number of labs using FFR shows that it is an underused modality. Integrating FFR into standing hemodynamic monitoring systems simplifies the use of this valuable tool. Today Volcano announced that it is offering FFR technology integrated with the existing systems manufactured by GE, Siemens, McKesson, and Mennen. (Read more...)

March 11, 2010
Volcano Announces Activities at the ACC 2010
The company announced its activities today at Annual Scientific Sessions of the American College of Cardiology (ACC) Conference taking place in Atlanta from March 14th to March 16th. Presentations and new product launches will continue Volcano's mission to demonstrate the limitations of angiography and the value of IVUS, FFR and OCT. (Read more...)

March 3, 2010
Functional Measurement Functioning Well at Volcano
Volcano Corporation (Nasdaq: VOLC) announced its fourth quarter results earlier today. And if the company's results are any indication, both IVUS and functional measurement (FM) technologies are increasingly finding a place in the interventional cardiologist's armamentarium. Volcano's sales of IVUS catheters were up 29%, but their FFR measurement product was up a whopping 92% over the previous fourth quarter. (Read more...)

March 3, 2010
Volcano Reports 44% Increase in Fourth Quarter Revenues
Volcano Corporation (Nasdaq: VOLC) said today that revenues for the quarter ended December 31, 2009, were $71.0 million, an increase of 44 percent versus revenues of $49.3 million in the fourth quarter a year ago. Revenues for the fourth quarter of 2009 included $5.8 million from Axsun Technologies, Inc., which Volcano acquired in the fourth quarter of 2008, and contributed $578,000 in revenues in the fourth quarter a year ago. The Company also reported that IVUS disposable sales grew 29%, while FM (Functional Measurement) disposable revenues increased 92%. (Read more...)

February 24, 2010
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time, (5 p.m., Eastern Standard Time), Wednesday, March 3, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Read more...)

February 11, 2010
IVUS vs. FFR -- Boston Style
Is Intravascular Ultrasound (IVUS) really "10 times better" than Fractional Flow Reserve (FFR)? Boston Scientific thinks so. (Read more...)

February 9, 2010
Volcano Has AAA Week: Accused, Approved and Acquired
Commentary from the Editor's Blog: Volcano Corporation (Nasdaq: VOLC) has had a pretty interesting week, from a jury ruling against the company to an FDA approval and a significant product acquisition. (Read more...)

February 9, 2010
Volcano Receives FDA Clearance to Market the Eagle Eye® Platinum Digital IVUS Catheter
Volcano Corporation (Nasdaq: VOLC), announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Eagle Eye® Platinum digital IVUS catheter in the United States. This state-of-the-art catheter offers all of the benefits of the predecessor Eagle Eye® Gold catheter, plus improved deliverability and the convenience of additional radiopaque markers. (Read more...)

February 9, 2010
Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract™ Thrombus Aspiration Catheter
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has acquired the Xtract™ Thrombus Aspiration Catheter device line from Lumen Biomedical. (Read more...)

February 5, 2010
Volcano Corporation Announces Litigation Status
Volcano Corporation (Nasdaq: VOLC) today announced that the jury in the litigation filed by Lightlab Imaging, Inc. on January 7, 2009 in the Superior Court of Massachusetts, Suffolk County reached a verdict against Volcano and its wholly owned subsidiary, Axsun Technologies. (Read more...)

January 11, 2010
Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance
Volcano Corporation (Nasdaq: VOLC) said today that it expects total revenues for fiscal 2009 will be approximately $228.0 million, with revenues in the fourth quarter of fiscal 2009 expected to be approximately $71.0 million, reflecting year-over-year revenue growth of approximately 33 percent. (Read more...)

January 5, 2010
Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the 28th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12. The presentation by Scott Huennekens, president and chief executive officer, will begin at 2 p.m., Pacific Standard Time, (5 p.m., Eastern Standard Time). (Read more...)

January 5, 2010
Volcano Corporation Announces Receipt of CE Mark for Its OCT Imaging System and Catheter
Volcano Corporation (Nasdaq: VOLC) announced today receipt of CE mark for their OCT (Optical Coherence Tomography) imaging system and catheter. Volcano's OCT product line is expected to complement its existing line of IVUS imaging catheters and pressure guide wires used for coronary imaging and lesion assessment. (Read more...)

December 22, 2009
Volcano Corporation Commends the Elevation of FFR to Level of Evidence A in New PCI Guidelines
Based on the strength of the latest clinical data supporting the usage of Fractional Flow Reserve (FFR), the American Heart Association (AHA), the American College of Cardiology (ACC), and the Society for Cardiovascular Angiography and Interventions (SCAI) elevated the level of evidence for FFR in their guidelines from Level B to Level A, the highest level possible. The guidelines suggest that FFR can be useful to evaluate intermediate blockages in coronary arteries, determine which lesions will benefit from stenting, and which should be treated with medical therapy alone. (Read more...)

December 15, 2009
Volcano Announces Installed Base Growth Milestone
Volcano Corporation (Nasdaq: VOLC), a leading developer of precision intravascular therapy guidance tools - including Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Forward Looking IVUS and Optical Coherence Tomography (OCT) - designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today the placement of over 2,500 s5 family consoles worldwide. The s5 family of consoles was first launched in April 2006, with more than 1,000 systems placed in the last 12 months alone. (Read more...)

December 4, 2009
Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging
Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: VOLC), today announced the initial development and successful testing of its novel integrated High Definition Swept Source -- or HDSS(tm) -- which is based on a non-laser source of photons. The HDSS is expected to enable high resolution at unprecedented speeds in medical imaging systems. Axsun believes this proprietary optical engine design raises the bar on imaging speed and overcomes fundamental limitations of laser-based designs for swept source OCT light sources. (Read more...)

November 25, 2009
Fractional Flow Reserve (FFR) Recognized in Guidelines, Not So Much In Reimbursement
Commentary From the Editor's Blog: Lower costs and a third less heart attacks and deaths. FFR should be in every cath lab, right? Yet currently penetration of this technology in the U.S. is only 5%. (Read more...)

November 25, 2009
Fractional Flow Reserve (FFR) Gains in Updated ACC/AHA/SCAI Guidelines
The use of Fractional Flow Reserve (FFR) to determine whether or not to treat a coronary blockage with angioplasty or stents has received a boost from the newly released "Focused Updates to the ACC/AHA/SCAI Guidelines on Percutanous Coronary Intervention." (Read more...)

November 24, 2009
Volcano Corporation Presentation at Piper Jaffray Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacture and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 1. (Read more...)

November 9, 2009
Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacture and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the Third Annual Canaccord Cardiovascular Conference on Tuesday, November 10. (Read more...)

November 5, 2009
Volcano Reports 22 Percent Increase in Third Quarter Revenues
Volcano Corporation (Nasdaq: VOLC) today reported revenues of $53.9 million for the third quarter of fiscal 2009. The results for the quarter ended September 30, 2009, represent an increase of 22 percent over revenues of $44.1 million in the third quarter of 2008. (Read more...)

September 24, 2009
Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcano's VH® IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks
PROSPECT results presented today include the landmark finding that angiographically mild lesions with certain morphologic features on grayscale and VH IVUS present with a 3 year cardiac event rate of 17%, versus other morphologies (indistinguishable by conventional angiograms) with three year event risks of less than 1%. (Read more...)

September 23, 2009
Volcano Corporation Praises FAME Study Results
The results of the prospective, multi-center trial at 12-months, originally published in the New England Journal of Medicine in 2009, demonstrate that patients with multi-vessel coronary artery disease who were treated by FFR guidance had a 34% reduction in death and myocardial infarction (MI) compared to angiographic guidance alone. The clinical benefit of FFR-guidance at two years showed the sustained reduction in death and heart attacks of 34%. (Read more...)

September 10, 2009
Volcano Corp. Announces Events at TCT Meeting
Volcano Corporation (Nasdaq: VOLC), a leader in the fields of Intravascular Ultrasound (IVUS) and Functional Measurement (FM) today announced a wide variety of events taking place at this year's Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco. A wide spectrum of activities will demonstrate how these technologies can improve the results obtained from angioplasty and stenting, and includes late-breaking clinical trials, symposia with panels of experts, live case demonstrations and an investor event. (Read more...)

September 1, 2009
Volcano Corporation Presentation at Weisel Conference to be Webcast
Volcano Corporation said today that it will be participating in the Thomas Weisel Partners Healthcare Conference 2009 on Wednesday, September 9. The presentation by John Dahldorf, chief financial officer, will begin at 8 a.m., Eastern Daylight Time (5 a.m., Pacific Daylight Time). (Read more...)

August 25, 2009
Volcano Corporation and Siemens Healthcare Announce Global Resale Agreement for Volcano IVUS/FFR Systems
Volcano Corporation (Nadsaq: VOLC), announced today that it has entered into a non-exclusive, global resale agreement with Siemens Healthcare, a sector of Siemens AG (NYSE: SI). Under this agreement, Siemens will resell Volcano-branded s5i IVUS/FFR systems and accessories alongside Siemens' Artis family of X-ray systems. (Read more...)

August 7, 2009
Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast
Volcano Corporation (Nadsaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the Canaccord Adams 29th Annual Global Growth Conference on Thursday, August 13. (Read more...)

August 4, 2009
Volcano Reports 30 Percent Increase in Second Quarter Revenues
Volcano's CEO Scott Huennekens states, "IVUS disposable revenues in the quarter were $31.8 million, a record quarter for this business, and a 26 percent increase over the second quarter a year ago. FM revenues in the quarter were a record $7.2 million, with FM disposable revenues increasing 75 percent over the second quarter a year ago. In addition, we continued our successful IVUS/FM console placement initiatives, placing 233 consoles versus 178 a year ago, an increase of 31 percent.... These results portray the value of our technology innovation, effective sales and marketing programs and the growing recognition among clinicians that IVUS and FM can play an important role in the diagnosis and treatment of patients. (Read more...)

July 27, 2009
Volcano Corporation Schedules Second Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC) will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time), Tuesday, August 4, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Read more...)

July 8, 2009
Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman
Volcano Corporation said today it has signed a termination agreement with its largest distributor in Japan, Goodman Company, Ltd. This agreement, which took effect today, will enable Volcano to accelerate its transition to a direct sales force in the market to support its intravascular ultrasound (IVUS) and Functional Measurement (FM) consoles and disposables, as well as products currently in development. (Read more...)

July 5, 2009
Interview with Giulio Guagliumi, MD About Optical Coherence Tomography and Stents
Dr. Giulio Guagliumi, an internationally recognized leader in the use of Optical Coherence Tomography (OCT) in the coronary arteries, practices in the Cardiovascular Department of Ospedali Riuniti di Bergamo in Bergamo, Italy. Dr. Guagliumi has been published in numerous peer-reviewed journals and is principal investigator in several clinical trials assessing the performance of stents inside the coronary artery, using OCT imaging. In this interview, he discusses the dynamic changes occurring with this technology. (Read more...)

May 25, 2009
Meeting to Highlight Use of New Imaging Technologies for Guiding Stent and Angioplasty Procedures
This week marks one of the first courses to focus exclusively on the range of innovative intravascular imaging and measurement technologies that have been gaining in use over the past couple of years. "OCT, IVUS, FFR: When, Where, How" will be held on May 28 and 29 in Bergamo, Italy. The course will utilize the newest innovations in Optical Coherence Tomography(OCT), Intravascular Ultrasound (IVUS), Virtual Histology (VH) and Fractional Flow Reserve (FFR) and how they can be used to optimize percutaneous procedures, such as angioplasty and stenting. (Read more...)

May 19, 2009
Optical Coherence Tomography (OCT) Presentations by Volcano at EuroPCR 2009
Volcano Corporation (Nasdaq: VOLC) today highlights its technology leadership position in the emerging field of Optical Coherence Tomography (OCT) at the EuroPCR conference in Barcelona, Spain. Volcano's wholly owned subsidiary, Axsun, has developed what we believe to be a truly revolutionary new class of ultra-miniaturized external cavity lasers that are expected to power the highest performance OCT systems for intracoronary and other medical imaging segments. (Read more...)

May 19, 2009
New Intravascular Ultrasound (IVUS) Study of Underexpanded Stents, Thrombosis and Restenosis
A study, published in the current issue of JACC Interventions, details 120 drug-eluting stent cases as viewed by intravascular ultrasound (IVUS) in order to examine characteristics that may lead to in-stent restenosis (ISR) or stent thrombosis. The researchers found that in cases of thrombosis, the proximal parts of many of the stents were inadequately expanded. An accompanying editorial suggests greater use of IVUS and more attention to detail can reduce the number of these adverse clinical events. (Read more...)

May 18, 2009
Volcano Announces Worldwide Exclusive Distribution Agreement With Lumen Biomedical for Xtract™ Thrombus Aspiration Catheter
Volcano Corporation (Nasdaq: VOLC) today announced an exclusive worldwide distribution agreement to initiate the formal launch of the Xtract™ thrombus aspiration catheter, manufactured by Lumen Biomedical. The Xtract thrombus aspiration catheter is available for immediate sale in the U.S. and Europe. This marks Volcano's entry into what some believe is a $70+ million aspiration market. (Read more...)

May 13, 2009
Volcano Corporation Presentation at JMP Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the Eighth Annual JMP Securities Research Conference on Monday, May 18. The presentation by John Dahldorf, chief financial officer, will begin at 3:00 p.m., Pacific Daylight Time (6:00 p.m., Eastern Daylight Time). (Read more...)

May 6, 2009
Volcano Corporation Presentation at Bank of America/Merrill Lynch Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the Bank of America and Merrill Lynch 2009 Health Care Conference on Thursday, May 14. The presentation by Scott Huennekens, president and chief executive officer, will begin at 11:20 a.m., Eastern Daylight Time (8:20 a.m., Pacific Daylight Time). (Read more...)

May 5, 2009
Volcano Reports 1st Quarter Revenues of $49 Million; IVUS and FM Businesses Grew 24%
Volcano Corp. (VOLC) reports a greater loss over the same period in 2008, due mainly to lower margins and the strength of the dollar. However, revenue of intravascular ultrasound and functional measurement products grew 24%. (Read more...)

May 4, 2009
Effectiveness in Stenting
As Volcano's CEO Scott Huennekens writes in an op-ed piece, there's a whole toolbox of devices and techniques that are candidates for "comparative effectiveness" in that they may be able to increase the success of interventional procedures -- or even target patients who need these procedures more accurately. (Read more...)

April 27, 2009
Volcano Corporation Schedules First Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced that it will report its operating results for the first quarter of fiscal 2009 on Tuesday, May 5. (Read more...)

March 27, 2009
Volcano Announces the Availability of Integrated Fractional Flow Reserve Technology on All Major Cardiovascular X-ray Angiography Systems
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced the availability of its integrated Fractional Flow Reserve (FFR) technology on all major cardiovascular x-ray systems: GE, Philips, Siemens and Toshiba. (Read more...)

March 27, 2009
Volcano Announces Schedule of Events at the ACC 2009, Integration into Indec and Medis Software Platforms
Joe Burnett, Vice President of Marketing at Volcano commented, "Three years ago, you could flip through the ACC program and see a couple of presentations on intravascular assessment using IVUS or FFR. This year, there are more than 50 presentations, case reviews and abstracts focused on FFR, IVUS, OCT, Forward-Looking IVUS, and VH® IVUS plaque composition. Word is getting out that more precise guidance during PCI is important, and the sheer number of talks focused on higher resolution tools, highlight the increased demand for access to these technologies. (Read more...)

March 26, 2009
ACC 2009 Sessions on Intravascular Imaging and Functional Measurement
The upcoming American College of Cardiology Annual Scientific Sessions, being held in Orlando, Florida from March 28-31 is featuring more than 50 presentations, case reviews and abstracts focused on intravascular imaging and functional measurement modalities, such as Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS, Optical Coherence Tomography (OCT), as well as newer technologies, like Forward-Looking IVUS and VH plaque composition. (Read more...)

February 20, 2009
Volcano Corporation Announces Webcast of February 25th Analyst Day
Volcano Corporation (Nasdaq: VOLC) will hold its 2009 Analyst Day on Wednesday, February 25, at the NASDAQ MarketSite in New York City. The webcast will begin at 10 a.m., Eastern Standard Time (7 a.m., Pacific Standard Time) and conclude at 2 p.m., Eastern Standard Time (11 a.m., Pacific Standard Time). (Read more...)

February 17, 2009
Volcano Reports Full Year Revenues Increase 31 Percent
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today reported that revenues for the full year 2008 increased 31 percent over full year 2007 and that revenues for the fourth quarter of 2008 increased 23 percent over revenues in the fourth quarter of 2007. (Read more...)

February 12, 2009
Volcano CEO to Present at Roth Capital Partners Conference; Webcast Announced
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the Roth Capital Partners 21st Annual Growth Stock Conference on Wednesday, February 18. (Read more...)

February 6, 2009
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced that it will report is operating results for the fourth quarter and all of fiscal 2008 on Tuesday, February 17. (Read more...)

January 20, 2009
Volcano Highlights Commitment, Market Acceptance of FFR Product Line
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today commented on the increased demand for their FFR and IVUS capable consoles, as well as their FFR pressure guide wires. Since announcement of the FAME study results at the TCT in October, the FFR option for Volcano's s5i integrated imaging console was included in more than 90% of all new orders. (Read more...)

January 17, 2009
FAME: "Back to the Future"
The leading story about stents this past week has been the publication of the FAME study and how a new St. Jude Medical device that measures blood pressures inside the artery can reduce the number of unnecessary angioplasty and stent procedures. Well...it's not a new device; it's definitely not a new concept; and St. Jude doesn't exactly get the credit for it either, since their chief role was to acquire the company that created the product. But it is an important study! (Read more...)

January 15, 2009
Better Outcomes for Stents When Fractional Flow Reserve (FFR) is Used
One-third fewer stents were used in the FFR group and the difference in outcomes at one year were significant: the FFR group showed a 28% lower incidence of major adverse cardiac events (repeat procedure to open the artery, heart attack or death) -- 18.3% vs. 13.2%. The implication in these results is that placing stents in lesions that are not responsible for ischemia is not only not necessary, but may cause worse outcomes. (Read more...)

January 15, 2009
Interview with Nico H. J. Pijls, MD, PhD
Angioplasty.Org conducts an exclusive interview with Dr. Nico Pijls, co-principal investigator of the FAME study (Fractional Flow Reserve vs. Angiography for Multivessel Evaluation) published today in the New England Journal of Medicine. The study concludes that "Routine measurement of FFR in patients with multivessel coronary artery disease who are undergoing PCI with drug-eluting stents significantly reduces the rate of the composite end point of death, nonfatal myocardial infarction, and repeat revascularization at 1 year." (Read more...)

January 7, 2009
Volcano Announces Closing of Axsun Technologies Acquisition
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it has closed its previously announced acquisition of Axsun Technologies, Inc. (Read more...)

January 6, 2009
Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the 27th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14. (Read more...)

December 23, 2008
Volcano Announces Acquisition of Axsun Technologies, Inc.
Volcano Corporation said today that it has entered into a definitive agreement to acquire Axsun Technologies, Inc., a privately-held company that is a leading developer and manufacturer of lasers and optical engines used in medical Optical Coherence Tomography (OCT) imaging systems and advanced photonic components and subsystems used in other industrial applications. (Read more...)

December 9, 2008
Interview with Szilard Voros, MD
Virtual Histology IVUS allows the cardiologist to see not only the plaque inside the artery, but what the composition of that plaque is. We discuss this new technology with one of the leading researchers in the field. (Read more...)

December 2, 2008
Volcano Corporation: Intravascular Imaging Ascending
In the midst of a recession, Volcano Corporation has shown a 19% increase in its stock value over the past six months. Its only competitor in the U.S. market suffered a 55% decrease. Why? (Read more...)

November 24, 2008
Volcano Corporation Presentation at Piper Jaffray Conference to Be Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the 20th Annual Piper Jaffray Health Care Conference on Tuesday, December 2. (Read more...)

November 5, 2008
78% Increase in Intravascular Ultrasound Systems Sales Boosts Volcano Quarterly Growth by 40%
For the quarter ended September 30, 2008, Volcano reported revenues of $44.1 million versus revenues of $31.5 million in the same period a year ago. The company said that its financial performance was driven by a 78 percent increase in intravascular ultrasound (IVUS) system revenues and a 29 percent increase in IVUS disposable revenues year-over-year. (Read more...)

November 5, 2008
Volcano Corporation To Report Third Quarter Results Today During Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC) will report its operating results for the third quarter and first nine months of fiscal 2008 on Wednesday, November 5. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time (5 p.m. Eastern Standard Time). (Read more...)

October 22, 2008
ODESSA Trial Looks Inside Drug-Eluting Stents With Optical Coherence Tomography (OCT)
(Updated) The results of ODESSA showed that OCT could indeed accurately measure strut coverage and NIH. An interesting data point was confirmation of the differences in the currently available DES. ODESSA looked at Cypher, Taxus, Endeavor and Bare Metal stents. The results showed that at six months, virtually all the struts of the Endeavor stent were covered -- the healing was even more complete than with bare metal stents, which reinforces reports of little or no very late stent thrombosis with the Endeavor. At the same time, an inverse relationship was observed between strut coverage and growth of neo-intimal hyperplasia (NIH) -- the Endeavor had the highest NIH growth of the DES (also called Late Loss) while the Cypher stent had the least Late Loss, but the highest number of uncovered struts. (Read more...)

October 15, 2008
Volcano Corporation Announces Launch of PrimeWire™ Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles
Volcano Corporation (Nasdaq: VOLC) today announced the launch of the PrimeWire™ Pressure Guidewire, and the s5-FFR Option for its existing installed base of s5 and s5i imaging consoles in the U.S. The PrimeWire is Volcano's newest pressure guidewire, capable of measuring pressure gradients across a lesion to determine the ischemic nature of the stenosis, and can also help determine the extent to which the blockage is flow-limiting. (Read more...)

October 13, 2008
Volcano Corporation Announces Schedule of Events for TCT (Transcatheter Cardiovascular Therapeutics Conference) 2008
The company has announced a wide range of events including live case transmissions, symposia to highlight new products and the clinical utility of Volcano technologies including FFR, IVUS, VH IVUS, OCT and Forward-Looking IVUS (Read more...)

October 6, 2008
Volcano Corporation Relocating Corporate Headquarters to San Diego
The new corporate headquarters is located in the Carmel Valley area of San Diego and now houses corporate executives, marketing, finance, accounting, corporate human resources, legal and catheter engineering. The company intends to expand its operations in San Diego in the future. The company's core research and development, manufacturing, operations, quality and local human resources functions will remain in Volcano's facilities in Rancho Cordova, CA. (Read more...)

September 20, 2008
Volcano Corporation Schedules Events for 2008 TCT Transcatheter Cardiovascular Therapeutics Meeting
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer of intravascular ultrasound (IVUS) and functional measurement (FM) technology, has scheduled several events to be held during the 2008 TCT meeting in Washington DC, being held October 12-17, 2008 at the Washington Convention Center. (Read more...)

September 15, 2008
Volcano Announces Resignation of Olav Bergheim from Board of Directors
The Company announced today that Olav B. Bergheim, the Volcano's chairman of the board, will resign from the board of directors effective as of the close of business on January 1, 2009. A co-founder of Volcano, Bergheim is the managing director of Fjord Ventures LLC, a venture capital firm he founded, and has served as chairman of Volcano's board since 2001. (Read more...)

September 2, 2008
Volcano's Virtual Histology Imaging Allows Major Drug Study (IBIS-2) to Measure "Vulnerable Plaque"
Volcano's VH® IVUS technology is being used in an imaging study of GlaxoSmithKline's novel investigational compound, Darapladib. Dubbed the IBIS-2 (Integrated Biomarker and Imaging Study) the study results demonstrate the benefits of VH® IVUS in drug development. (Read more...)

July 29, 2008
Volcano Corporation Schedules Second Quarter Conference Call and Webcast
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the second quarter and first six months of fiscal 2008 on Tuesday, August 5. (Read more...)

July 8, 2008
Intravascular Ultrasound (IVUS) May Reduce Drug-Eluting Stent Thrombosis by a Third
A provocative study in the current issue of the European Heart Journal concludes that: "IVUS guidance during DES implantation has the potential to influence treatment strategy and reduce both DES thrombosis and the need for repeat revascularization." The results were striking, surprising even the investigators. At 12 months, definite stent thrombosis had occurred in 0.7% of the patients in whom intravascular ultrasound guidance had been utilized, but in patients where IVUS was not used, the stent thrombosis rate was 2.0%, almost three times higher. (Read more...)

June 28, 2008
Interview with Ron Waksman, MD, FACC
Our IVUS Center features a discussion about an important new study, just published in the European Heart Journal, showing that IVUS guidance can improve outcomes with drug-eluting stents, including significantly lower rates of stent thrombosis. (Read more...)

June 3, 2008
When Can I Stop Taking Plavix? -- A New Imaging Modality May Help Patients and Physicians Determine Optimal Duration of Antiplatelet Therapy in the Not-Too-Distant Future
(Updated) The question on the minds of a great many patients who have had a drug-eluting stent implanted is: "When can I stop taking Plavix? When will my drug-eluting stent be completely healed?" It's THE question of the day, and no one is really sure of the answer. However, a new imaging technology, called Optical Coherence Tomography or OCT, may help with this issue in the not-too-distant future.. (Read more...)

May 19, 2008
Volcano Corporation Presentation at JMP Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC), a provider of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Seventh Annual JMP Securities Research Conference on Tuesday, May 20. (Read more...)

May 19, 2008
Volcano Announces Acquisition of Novelis, Inc.
Novelis' Forward-Looking IVUS technology platform is expected to enable Volcano to offer an expanded line of minimally invasive diagnostic and therapeutic devices, especially in the area of chronic total occlusions (CTO). (Read more...)

May 15, 2008
Intravascular Ultrasound (IVUS) Use Growing with Integration into Routine Cath Lab Imaging
Intravascular Ultrasound, or IVUS, is an imaging technology that looks at arteries from the inside out. Invented two decades ago, IVUS recently has been gaining in usage due to safety concerns about stent thrombosis and proper stent placement during angioplasty. (Read more...)

May 12, 2008
Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System; Presence at the EuroPCR08 will highlight choice of different modalities available on single integrated imaging platform
Scott Huennekens, President and Chief Executive Officer of Volcano, commented, "Reaching this milestone as quickly as we have is a clear indication of the clinical adoption of IVUS and FFR, and the competitiveness of our product. More and more physicians are using intravascular imaging to measure lesion significance and improve PCI technique. The ease of use and flexibility of our newest systems have been very well received. These new systems are gaining traction with both new IVUS users, as well as those who are looking to replace their legacy IVUS technology." (Read more...)

May 8, 2008
Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
Volcano Corporation (Nasdaq: VOLC) announced today the first human procedure using the Volcano OCT Imaging catheter. The procedure was performed by Dr. Patrick Serruys at the Thoraxcenter, in Rotterdam, Netherlands. Volcano OCT will complement its existing line of IVUS imaging catheters and pressure guidewires used for coronary imaging and lesion assessment. (Read more...)

May 7, 2008
Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the first quarter of fiscal 2008. (Read more...)

May 5, 2008
Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
SATURN is a 104-week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) imaging study of approximately 1,300 patients at 170 centres This study by AstraZeneca is designed to measure the impact of CRESTOR™ (rosuvastatin) 40 mg and atorvastatin (Lipitor®) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare the effects of these two statins on the ability to decrease progression or induce regression of atherosclerosis, the main cause of cardiovascular disease, following two years of treatment in patients with coronary artery disease. (Read more...)

April 29, 2008
Volcano Corporation Schedules First Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement(FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the first quarter of fiscal 2008 on Wednesday, May 7. (Read more...)

March 31, 2008
Volcano Corporation Announces North America Resale Agreement with Royal Philips Electronics
Volcano Corporation, leading manufacturer of intravascular ultrasound (IVUS), announced today that it has entered into a non-exclusive, resale agreement covering North America with Royal Philips Electronics. Under this agreement, Philips will resell Volcano-branded s5i IVUS systems and accessories alongside of the Philips Allura Xper FD X-ray systems. (Read more...)

March 28, 2008
Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
Volcano Corporation, a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today the U.S. and European launch of the s5-Revo and s5-FFR (fractional flow reserve) options for the s5i integrated Imaging platform. (Read more...)

March 27, 2008
Intravascular Ultrasound (IVUS) Events at American College of Cardiology Annual Meeting
Intravascular ultrasound (IVUS) is scheduled to be part of 29 separate sessions at this weekend's annual meeting of cardiologists in Chicago. In addition, IVUS will be used by interventionalists who will be performing 14 live procedures, to be broadcast to the Convention Center at McCormick Place from Lenox Hill Hospital in New York, and other medical centers in California, London, Germany, Japan and Australia. (Read more...)

March 12, 2008
Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC), a leading provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, will be participating in the Cowen and Company 28th Annual Health Care Conference on Monday, March 17. The presentation by president and CEO, Scott Huennekens, will begin at 3:15 p.m., Eastern Daylight Time (12:15 Pacific Daylight Time). (Read more...)

February 12, 2008
Volcano Reports 35% Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46%
"This growth in our IVUS business occurred despite a sluggish global PCI market. We believe the ease of use and integration provided by our s5 family of consoles, along with a growing volume of data demonstrating the value of IVUS in stenting procedures, is driving our increased market presence in the IVUS arena," he added. "We are encouraged by what appear to be recent favorable trends in stenting procedures and believe this will further the growth of our IVUS offerings," he continued. (Read more...)

February 7, 2008
Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
These two new product offerings now enable rotational IVUS and FFR to operate on the same integrated Volcano s5 Imaging System as Volcano's previous line of phased array IVUS catheters and functionality. For the first time, physicians can choose among three powerful diagnostic tools -- all on the same integrated IVUS platform. (Read more...)

December 10, 2007
Volcano Announces Agreement to Acquire CardioSpectra
Volcano Corporatio, a provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of vascular and structural heart disease, said today that it has reached a definitive agreement to acquire CardioSpectra, Inc., a privately-held company developing innovative Optical Coherence Tomography (OCT) technology. CardioSpectra's unique OCT imaging system is expected to complement Volcano's existing product offerings and will further enhance Volcano's position as an imaging technology leader in the field of interventional medicine. (Read more...)

November 8, 2007
Volcano Reports Record Third Quarter Revenues
Volcano Corporation, a leading provider of intravascular ultrasound (IVUS) and functional measurement (FM) products, today reported record revenues of $31.5 million, a 13 percent increase over revenues of $27.8 million in the third quarter a year ago. (Read more...)

November 8, 2007
Cordis Europe Partnering With Volcano Europe to Provide Access to Intravascular Imaging (IVUS) for Use in Drug-Eluting Stent Procedures
One of the major drug-eluting stent makers seems to agree with the idea that intravascular ultrasound (IVUS) guidance is critical for the proper placement of their devices. This move is a significant one for Volcano, which has long been trying to educate the interventional cardiology community about IVUS. (Read more...)

October 22, 2007
Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
Volcano Corporation, a leading manufacturer of intravascular ultrasound (IVUS) and functional measurement (FM) technology, announced today activities planned for the 2007 Transcatheter Cardiovascular Therapeutics (TCT) conference that will take place from October 20th to October 25th in Washington D.C. (Read more...)

October 22, 2007
Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
3,000 patients will be studied as part of a multi-center IVUS sub-study, part of the Cardiovascular Research Foundation's ADAPT-DES Study to quantify the causes and cures of thrombosis in drug-eluting stents. (Read more...)

September 4, 2007
Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
Volcano Corporation, a provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of vascular and structural heart diseases, said today that it will be participating in the Bear Stearns 2007 Healthcare Conference on Tuesday, September 11. (Read more...)

July 24, 2007
Volcano Corporation Announces Japan Approval of the s5i Integrated IVUS Platform
Volcano Corporation today announced approval of the s5i Integrated IVUS System by necessary regulatory authorities in Japan, granting entry into the Japanese market. Volcano expects to launch the s5i into Japan, which represents the largest Intravascular Ultrasound (IVUS) market worldwide, during the current quarter. (Read more...)

May 30, 2007
Most Heart Stents Are Placed Imperfectly, Increasing Risk of Heart Attack or Reclosure
Results of a new study show that stent placement involves a "geographic miss" two-thirds of the time, resulting in a three-fold increased risk of heart attack and a two-fold increase in reintervention. The article includes interviews with Dr. Marco Costa of the University of Florida College of Medicine in Jacksonville, chief investigator for the S.T.L.L.R. study, and Dr. Antonio Colombo of Columbus and San Raffaele Hospitals in Milan, Italy (Read more...)

May 7, 2007
Volcano Corporation Reports 49 Percent Increase in Revenues; IVUS Disposable Sales Increase 33 Percent
(source: Volcano Corporation)
Volcano Corporation, a leading provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of vascular and structural heart diseases, today reported that revenues in the first quarter of 2007 increased 49 percent over revenues in the first quarter a year ago. (Read more...)

April 25, 2007
Volcano Corporation Schedules First Quarter Conference Call, Webcast
(source: Volcano Corporation)
The company will hold a conference call to discuss its financial results and operating activities to all interested parties at 2 p.m., Pacific Daylight Time (5 p.m. Eastern Daylight Time), Monday, May 7, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Read more...)

April 18, 2007
COURAGE, SPIRIT Data May Support Role of Advanced Imaging and Diagnosis With IVUS and FFR
(source: Volcano Corporation)
The results of recent studies presented at this year's American College of Cardiology may support the role played by intravascular ultrasound (IVUS) and fraction flow reserve (FFR) in diagnosing the need for stenting more accurately than standard angiography and, when the use of a stent is indicated, aiding in the accuracy of stent placement. (Read more...)

April 4, 2007
Volcano Corp. Reports Use of Intravascular Ultrasound (IVUS) Increasing as Physicians Refocus on Stent Technique
While use in the United States of DES has decreased from 89% to an estimated 70% over the past year, driven by concerns over stent thrombosis causing heart attacks, and confidence in Bare Metal Stent (BMS) safety, for the same period, Volcano has seen an increase of 25% in IVUS revenue, demonstrating more reliance on detailed imaging to guide optimal DES and BMS placement. (Read more...)

April 3, 2007
Volcano Corporation and ev3 Inc. Announce Joint Marketing and Distribution Agreement
Under the terms of the agreement, Volcano will have the opportunity to sell ev3's SpiderFX Embolic Protection Device in conjunction with their Intravascular Ultrasound (IVUS) and Functional Measurement (FM) devices for use in saphenous vein grafts (SVG's) in the U.S. (Read more...)

February 13, 2007
Volcano Corporation and Cordis Endovascular Japan Announces Distribution Agreement for IVUS Indications
(source: Volcano Corporation)
Volcano Corporation today announced the signing of a distribution agreement with Johnson & Johnson K.K., Medical Company.The agreement appoints Cordis Endovascular Systems Japan as a distributor of IVUS products for use in peripheral and endovascular procedures in Japan.

November 27, 2006
Intravascular Ultrasound (IVUS) Imaging Technology May Help Lower Rates of Late Stent Thrombosis
While there are a number of causes of late stent thrombosis that have been identified, one of the factors most associated is poor apposition (incomplete expansion or suboptimal positioning) of the drug-eluting stent. A recent presentation by Dr. William Wijns of Aalst, Belgium at last month's TCT meeting showed that in 77% of the late stent thrombosis cases (clotting one year after implantation) the stent showed incomplete apposition (mal-apposition was seen in only 12% of cases where there was no stent thrombosis). (Read more...)

November 13, 2006
Volcano Announces Clinical Review of Key Presentations From TCT 2006
(source: Volcano Corporation)
The whole field of intravascular ultrasound (IVUS) is gaining in importance as problems are surfacing about drug-eluting stents. The value of IVUS

October 20, 2006
Volcano Corporation and MediGuide Ltd. Announce Collaboration for Advanced Imaging and Navigation Technology
(source: Volcano Corporation)
The companies initially plan to develop Guided IVUS (GIVUS), a product which will integrate MediGuide's Medical Positioning System (MPS) with Volcano's intravascular ultrasound (IVUS) system. This combination of technologies will expand the two dimensional aspect of the existing IVUS image into a three dimensional image that is designed to provide more useful clinical information, allow for easier interpretation of the image by interventional cardiologists and improve the clinical utility of the image.

October 11, 2006
Volcano Announces First Permanent Installations of the Integrated s5i IVUS Imaging System
(source: Volcano Corporation)
The company today announced the first permanent installations of the s5i IVUS (intravascular ultrasound) imaging system in both the U.S. and Europe. The s5i is Volcano's first IVUS system that can be integrated into any new or existing cath lab configuration. Through a series of customizable components, Volcano can now tailor an integrated IVUS solution to the unique user and workflow needs for any vendor's cath lab type or configuration.

August 24, 2006
GE Healthcare and Volcano Corporation Announce FDA Clearance of Fully-Integrated Intravascular Ultrasound Imaging on the Innova Platform
(source: GE Healthcare and Volcano Corporation)
The FDA has given clearance to a new integrated state-of-the-art intravascular ultrasound (IVUS) platform with an all-digital X-ray cath lab imaging system. (Read more...)

August 30, 2006
Abbott Announces Completion of Enrollment in Groundbreaking Vulnerable Plaque Study
Utilizing the Volcano Therapeutics' intravascular ultrasound imaging system, the PROSPECT study, headed by Dr. Gregg Stone of Columbia University Medical Center in New York, will attempt to more clearly define who is at risk for a heart attack by looking at vulnerable plaque, not just plaque "build-up". (Read more...)